These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Bortolotto S; Chiadò-Piat L; Cavalla P; Bosone I; Chiò A; Mauro A; Schiffer D Int J Cancer; 2000 Nov; 88(4):554-7. PubMed ID: 11058870 [TBL] [Abstract][Full Text] [Related]
3. CDKN2A, CDKN2B and p14ARF are frequently and differentially methylated in ependymal tumours. Rousseau E; Ruchoux MM; Scaravilli F; Chapon F; Vinchon M; De Smet C; Godfraind C; Vikkula M Neuropathol Appl Neurobiol; 2003 Dec; 29(6):574-83. PubMed ID: 14636164 [TBL] [Abstract][Full Text] [Related]
4. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. Burns KL; Ueki K; Jhung SL; Koh J; Louis DN J Neuropathol Exp Neurol; 1998 Feb; 57(2):122-30. PubMed ID: 9600204 [TBL] [Abstract][Full Text] [Related]
5. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index. Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306 [TBL] [Abstract][Full Text] [Related]
6. CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex. Alves MK; Faria MH; Neves Filho EH; Ferrasi AC; Pardini MI; de Moraes Filho MO; Rabenhorst SH Int J Surg; 2013; 11(7):549-53. PubMed ID: 23721661 [TBL] [Abstract][Full Text] [Related]
7. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors. Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008 [TBL] [Abstract][Full Text] [Related]
8. CDKN2A deletion in pediatric versus adult glioblastomas and predictive value of p16 immunohistochemistry. Purkait S; Jha P; Sharma MC; Suri V; Sharma M; Kale SS; Sarkar C Neuropathology; 2013 Aug; 33(4):405-12. PubMed ID: 23311918 [TBL] [Abstract][Full Text] [Related]
9. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Nielsen GP; Burns KL; Rosenberg AE; Louis DN Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476 [TBL] [Abstract][Full Text] [Related]
10. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes. Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049 [TBL] [Abstract][Full Text] [Related]
11. 9p21 and 13q14 dosages in ependymomas. A clinicopathologic study of 101 cases. Rajaram V; Leuthardt EC; Singh PK; Ojemann JG; Brat DJ; Prayson RA; Perry A Mod Pathol; 2004 Jan; 17(1):9-14. PubMed ID: 14631364 [TBL] [Abstract][Full Text] [Related]
12. Gene expression patterns in ependymomas correlate with tumor location, grade, and patient age. Korshunov A; Neben K; Wrobel G; Tews B; Benner A; Hahn M; Golanov A; Lichter P Am J Pathol; 2003 Nov; 163(5):1721-7. PubMed ID: 14578171 [TBL] [Abstract][Full Text] [Related]
14. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation. Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918 [TBL] [Abstract][Full Text] [Related]
15. The rate of homozygous CDKN2A/p16 deletions in glioma cell lines and in primary tumors. Hartmann C; Kluwe L; Lücke M; Westphal M Int J Oncol; 1999 Nov; 15(5):975-82. PubMed ID: 10536182 [TBL] [Abstract][Full Text] [Related]
16. p16INK4a and p19INK4d mRNA expression in neuroglial tumours: correlation with Ki67 proliferation index. Bouvier-Labit C; Civatte M; Bartoli C; Renaud W; Pellissier JF; Figarella-Branger D Neuropathol Appl Neurobiol; 1999 Oct; 25(5):408-16. PubMed ID: 10564531 [TBL] [Abstract][Full Text] [Related]
17. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype. Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600 [TBL] [Abstract][Full Text] [Related]
18. A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment. Hashimoto N; Suzuki T; Ishizawa K; Nobusawa S; Yokoo H; Nishikawa R; Yasuda M; Sasaki A Brain Tumor Pathol; 2023 Jul; 40(3):163-175. PubMed ID: 37322295 [TBL] [Abstract][Full Text] [Related]
19. Association of low p16INK4a and p15INK4b mRNAs expression with their CpG islands methylation with human hepatocellular carcinogenesis. Qin Y; Liu JY; Li B; Sun ZL; Sun ZF World J Gastroenterol; 2004 May; 10(9):1276-80. PubMed ID: 15112341 [TBL] [Abstract][Full Text] [Related]
20. Cyclin D1 and MIB-1 immunohistochemistry in ependymomas: a study of 41 cases. Prayson RA Am J Clin Pathol; 1998 Nov; 110(5):629-34. PubMed ID: 9802348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]